Viewing Study NCT06622304



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06622304
Status: COMPLETED
Last Update Posted: None
First Post: 2024-09-29

Brief Title: Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
Sponsor: None
Organization: None

Study Overview

Official Title: Mendelian Randomization Analysis of Drug Targets Exploring the Impact of Antihypertensive and Lipid-Lowering Therapies on Inflammatory Cytokines
Status: COMPLETED
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MRDLT
Brief Summary: This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach By leveraging genome-wide association studies GWAS and expression quantitative trait loci eQTL data the study evaluates the effects of angiotensin-converting enzyme inhibitors ACEIs angiotensin receptor blockers ARBs HMG-CoA reductase inhibitors PCSK9 inhibitors and NPC1L1 inhibitors on key inflammatory cytokines such as IL-1β TNF-α CRP and MCP-1 The findings aim to provide insights into the prevention and control of excessive inflammatory responses particularly in patients with hypertension and dyslipidemia by assessing the causal effects of these therapies
Detailed Description: This observational study focuses on elucidating the causal relationships between commonly prescribed antihypertensive drugs ACEIs and ARBs and lipid-lowering drugs HMG-CoA reductase inhibitors PCSK9 inhibitors and NPC1L1 inhibitors with various inflammatory cytokines including IL-1β TNF-α CRP MCP-1 and IFN-γ using a drug-targeted Mendelian randomization MR framework The study employs large-scale genetic data from European populations drawing from genome-wide association studies GWAS and expression quantitative trait loci eQTL datasets to construct instrumental variables that mimic the effects of drug exposure

The primary aim is to explore how these pharmaceutical interventions influence inflammatory pathways at the molecular level The use of MR methods enables causal inference by utilizing genetic variants within or near drug-target genes allowing for the estimation of downstream effects similar to those produced by actual drug interventions Key statistical methods including inverse variance weighting and sensitivity analyses are applied to ensure robustness and validity of the results

This research provides critical evidence for the selection of antihypertensive and lipid-lowering therapies that not only manage cardiovascular risk factors but also modulate inflammation contributing to personalized medicine strategies for patients with chronic inflammatory conditions Furthermore the findings have broader implications for drug repurposing and the development of new therapeutic targets aimed at mitigating inflammatory processes that underlie various chronic diseases

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None